The wildly beating heart, fatigue and other debilitating symptoms are well known to the many millions of people impacted by atrial fibrillation. Some of those who have afib may have no outward symptoms, but are still at risk of serious and long-term damage to the heart. Symptoms or not, rate control is the common treatment …
Read More
In this interview, Dr. Daniel Singer updates us on the new anticoagulants for atrial fibrillation stroke prevention that he presented about at Boston Atrial Fibrillation Symposium. He provided an update on rivaroxaban (Xarelto), apixaban (Eliquis), dabigatran (Pradaxa), and edoxaban, and mentioned that all were better than warfarin (Coumadin) in preventing intracranial bleeding (bleeding in the …
Read More
Dr. John Mandrola, a cardiac electrophysiologist in Louisville, Kentucky, who blogs at Dr. John M, live-blogged the 2012 Boston Atrial Fibrillation Symposium. He has given us permission to reprint his blog posts for the afib community. You will find them here: Recap of Boston Atrial Fibrillation Symposium 2012 – Guest Posts by Dr. John Mandrola …
Read More
Our January EP Lab Digest Patient Perspective column, Stuck in the Middle: Afib Patients on Rate Control, focuses on how rate control treatment (such as beta blockers) alone impacts the quality of life of those living with atrial fibrillation. The column also explores things doctors and patients may wish to consider in determining an appropriate …
Read More
In follow up to our announcement yesterday of the Top Ten Atrial Fibrillation Videos of 2011, StopAfib.org now unveils the Top Ten Atrial Fibrillation Articles of 2011. Major topics of interest to the atrial fibrillation patient community this year were afib stroke prevention and the CHADS2 and CHA2DS2-VASc scoring tools that determine the need for …
Read More
StopAfib.org has announced the Top Ten Atrial Fibrillation Videos of 2011. Afib stroke prevention again topped the list, with stories about warfarin (Coumadin), alternatives such as dabigatran (Pradaxa) and rivaroxaban (Xarelto), and the CHADS2 and CHA2DS2-VASc scoring tools for determining whether anticoagulants are needed. Other popular topics included sleep apnea, catheter ablation, and maze procedures (surgical …
Read More
A recent New England Journal of Medicine article reported on the results of the ARISTOTLE trial comparing the effectiveness of apixaban and warfarin for atrial fibrillation stroke prevention. Apixaban was shown to be superior to warfarin in preventing afib strokes. Learn more about the results of this trial at: Apixaban Superior to Warfarin for Atrial …
Read More
The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to …
Read More
In this important video interview at Venice Arrhythmias, Professor Gregory Lip discusses the importance of the CHA2DS2-VASc scoring tool for predicting atrial fibrillation stroke risk and why aspirin is not appropriate for preventing strokes. Watch the video at: Professor Gregory Lip Discusses CHA2DS2-VASc Tool for Predicting Stroke Risk in Atrial Fibrillation — Video
Read More
The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at: FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention
Read More